New Therapeutic Strategies for Type 2 Diabetes CME

Ahmad Yehya; Archana R. Sadhu

doi:10.14797/mdcj-14-4-281

New Therapeutic Strategies for Type 2 Diabetes ^CME

Ahmad Yehya, Archana R. Sadhu

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Pharmacological options for treatment of type 2 diabetes (T2D) have advanced rapidly during the last 10 years, allowing clinicians to target different pathophysiological defects in this disease. There are currently 12 different classes of drugs available to treat T2D. The most exciting development is the demonstration of cardiovascular (CV) benefits from two of these new classes, the glucagon-like peptide-1 receptor agonists (GLP-1 RA) and selective sodium glucose transporter 2 (SGLT2) inhibitors. These drugs have challenged conventional algorithms in the management of T2D by exceeding expectations in cardiovascular outcome trials and demonstrating an unexpected reduction in CV events. This review focuses on the physiologic actions and the CV outcomes associated with dipeptidyl peptidase-4 (DPP-4) inhibitor, GLP-1 RA, and SGLT2 inhibitor use. Understanding their potential may revolutionize our approach to the management of T2D.

Original language	English (US)
Pages (from-to)	281-288
Number of pages	8
Journal	Methodist DeBakey cardiovascular journal
Volume	14
Issue number	4
DOIs	https://doi.org/10.14797/mdcj-14-4-281
State	Published - Oct 1 2018

Keywords

DPP-4
GLP-1 RA
SGLT2
cardiovascular disease
heart failure
incretins
myocardial infarction
type 2 diabetes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.14797/mdcj-14-4-281

Cite this

@article{ded83dcfd17042eab4d30698706c07fe,

title = "New Therapeutic Strategies for Type 2 Diabetes CME",

abstract = "Pharmacological options for treatment of type 2 diabetes (T2D) have advanced rapidly during the last 10 years, allowing clinicians to target different pathophysiological defects in this disease. There are currently 12 different classes of drugs available to treat T2D. The most exciting development is the demonstration of cardiovascular (CV) benefits from two of these new classes, the glucagon-like peptide-1 receptor agonists (GLP-1 RA) and selective sodium glucose transporter 2 (SGLT2) inhibitors. These drugs have challenged conventional algorithms in the management of T2D by exceeding expectations in cardiovascular outcome trials and demonstrating an unexpected reduction in CV events. This review focuses on the physiologic actions and the CV outcomes associated with dipeptidyl peptidase-4 (DPP-4) inhibitor, GLP-1 RA, and SGLT2 inhibitor use. Understanding their potential may revolutionize our approach to the management of T2D.",

keywords = "DPP-4, GLP-1 RA, SGLT2, cardiovascular disease, heart failure, incretins, myocardial infarction, type 2 diabetes",

author = "Ahmad Yehya and Sadhu, {Archana R.}",

year = "2018",

month = oct,

day = "1",

doi = "10.14797/mdcj-14-4-281",

language = "English (US)",

volume = "14",

pages = "281--288",

journal = "Methodist DeBakey cardiovascular journal",

issn = "1947-6094",

publisher = "Methodist DeBakey Heart & Vascular Center",

number = "4",

}

TY - JOUR

T1 - New Therapeutic Strategies for Type 2 Diabetes CME

AU - Yehya, Ahmad

AU - Sadhu, Archana R.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Pharmacological options for treatment of type 2 diabetes (T2D) have advanced rapidly during the last 10 years, allowing clinicians to target different pathophysiological defects in this disease. There are currently 12 different classes of drugs available to treat T2D. The most exciting development is the demonstration of cardiovascular (CV) benefits from two of these new classes, the glucagon-like peptide-1 receptor agonists (GLP-1 RA) and selective sodium glucose transporter 2 (SGLT2) inhibitors. These drugs have challenged conventional algorithms in the management of T2D by exceeding expectations in cardiovascular outcome trials and demonstrating an unexpected reduction in CV events. This review focuses on the physiologic actions and the CV outcomes associated with dipeptidyl peptidase-4 (DPP-4) inhibitor, GLP-1 RA, and SGLT2 inhibitor use. Understanding their potential may revolutionize our approach to the management of T2D.

AB - Pharmacological options for treatment of type 2 diabetes (T2D) have advanced rapidly during the last 10 years, allowing clinicians to target different pathophysiological defects in this disease. There are currently 12 different classes of drugs available to treat T2D. The most exciting development is the demonstration of cardiovascular (CV) benefits from two of these new classes, the glucagon-like peptide-1 receptor agonists (GLP-1 RA) and selective sodium glucose transporter 2 (SGLT2) inhibitors. These drugs have challenged conventional algorithms in the management of T2D by exceeding expectations in cardiovascular outcome trials and demonstrating an unexpected reduction in CV events. This review focuses on the physiologic actions and the CV outcomes associated with dipeptidyl peptidase-4 (DPP-4) inhibitor, GLP-1 RA, and SGLT2 inhibitor use. Understanding their potential may revolutionize our approach to the management of T2D.

KW - DPP-4

KW - GLP-1 RA

KW - SGLT2

KW - cardiovascular disease

KW - heart failure

KW - incretins

KW - myocardial infarction

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85061962741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061962741&partnerID=8YFLogxK

U2 - 10.14797/mdcj-14-4-281

DO - 10.14797/mdcj-14-4-281

M3 - Review article

C2 - 30788014

AN - SCOPUS:85061962741

SN - 1947-6094

VL - 14

SP - 281

EP - 288

JO - Methodist DeBakey cardiovascular journal

JF - Methodist DeBakey cardiovascular journal

IS - 4

ER -